Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00661466 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of A Collagen Bupivacaine Implant in Patients After Gastrointestinal Surgery
A Phase 2 study, sponsored by Innocoll.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00661466 is a Phase 2 study that was terminated before completion, run by Innocoll. The registered enrollment target is 7 participants.
The verdict
NCT00661466, a Phase 2 study, was terminated before completion, sponsored by Innocoll.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the CollaRx Bupivacaine Implant (bupivacaine sponge) is safe and effective in reducing the amount of narcotic pain medication needed to control pain during the first 24 hours after gastrointestinal (GI) surgery.
Interventions
- DRUG Placebo
- DRUG Bupivacaine Collagen Sponge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2008-07-24 |
| Est. Completion | 2009-02-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00661466
The ClinicalTrials.gov registry entry for NCT00661466 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Innocoll, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00661466 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00661466 about?
NCT00661466 is a clinical study titled "Efficacy and Safety of A Collagen Bupivacaine Implant in Patients After Gastrointestinal Surgery". The purpose of this study is to determine whether the CollaRx Bupivacaine Implant (bupivacaine sponge) is safe and effective in reducing the amount of narcotic pain medication needed to control pain during the first 24 hours after gastrointestinal (GI) surgery.
What is the current status of trial NCT00661466?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2008-07-24. Estimated completion is 2009-02-10.
What interventions are being tested in trial NCT00661466?
The interventions under investigation include: Placebo (DRUG), Bupivacaine Collagen Sponge (DRUG).
Who is sponsoring clinical trial NCT00661466?
This trial is sponsored by Innocoll, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.